Honiton Hearing Centre
  • Youtube
  • Twitter
  • Facebook
  • Linkedin
  • Gplus
  • Home
  • Services
    • Hearing Test
    • Hearing Protection
    • Hearing Aids
    • Tinnitus Control
    • Ear wax removal
    • Repairs
  • Testimonials
  • FAQ
  • News
  • Contact
  • Videos
    • What type of hearing aid do you need?
    • Ear Syringing Honiton Devon
    • Hopi Candles, Myth?
    • Hearing aid batteries Honiton
    • Hearing Test
    • How to change the wax guard
    • Ear Irrigation
    • Microsuction Ear wax Removal
  • Menu

Primary Progressive Aphasia Memory Loss Measured

January 25, 2021/in Exeter hearing aids, News /by admin

Primary Progressive Aphasia Memory Loss Measured

   

Primary Progressive Aphasia Memory Loss Measured

Primary progressive aphasia is a rare neurodegenerative condition characterised by prominent language problems that worsen over time. About 40% of people with the condition have underlying Alzheimer’s disease. But a new study has found that people with the condition may not develop the memory problems associated with Alzheimer’s disease. The study is published in the January 13, 2021, online issue of Neurology, the medical journal of the American Academy of Neurology (AAN). A summary of the research was also published on the AAN website.

Related article: Speech-Disrupting Brain Disease Reflects Patients’ Native Tongue

“While we knew that the memories of people with primary progressive aphasia were not affected at first, we did not know if they maintained their memory functioning over years,” said study author M. Marsel Mesulam, MD, of Northwestern University Feinberg School of Medicine in Chicago and a Fellow of the American Academy of Neurology. “This has been difficult to determine because most memory tests rely on verbal skills that these people have lost or are losing.”

Honiton hearing centre

Cancer drug may help with sound processing, memory loss

The study included 17 people with primary progressive aphasia associated with Alzheimer’s disease. They were compared to 14 people who had typical Alzheimer’s disease with memory loss.

Researchers tested memory skills of the people with primary progressive aphasia by showing them pictures of common objects. After waiting 10 minutes, they were shown the same pictures along with others and had to indicate whether they had seen the picture before. This test was given once and then again an average of 2.4 years later. The people with typical Alzheimer’s disease listened to a list of common words and were later given the same words along with others and asked to choose the ones they had heard before. They were tested once and then again an average of 1.7 years later.

Both groups also had tests of their language skills. Brain scans were taken of the people with primary progressive aphasia to look at how the disease was affecting their brains, especially in the areas related to memory.

The people with primary progressive aphasia had no decline in their memory skills when they took the tests a second time. At that point, they had been showing symptoms of the disorder for an average of six years. In contrast, their language skills declined significantly during the same period. For the people with typical Alzheimer’s disease, their verbal memory and language skills declined with equal severity during the study.

Exeter ear wax removal

Researchers had brain autopsies from eight of the people with primary progressive aphasia and all of the people with typical Alzheimer’s disease. The people with primary progressive aphasia had similar amounts of the plaques and tangles that are signs of Alzheimer’s disease as the people with typical Alzheimer’s, Mesulam said. Left sided asymmetry of brain shrinkage and a lower incidence of brain proteins known as ApoE4 and TDP-43 were identified as potential contributors to the preservation of memory in this rare type of Alzheimer’s disease.

“More research is needed to help us determine what factors allow these people to show this resilience of memory skills even in the face of considerable Alzheimer’s disease pathology in the brain,” Mesulam said.

Limitations of the study are the relatively small sample size and that autopsies were not available for all of the primary progressive aphasia cases.

The study was supported by the National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Neurological Disorders and Stroke, The Davee Foundation, and The Jeannine Jones Fund.

Original Paper: Mesulam MM, Coventry C, Kuang A, et al. Memory resilience in Alzheimer’s disease with primary progressive aphasia. Neurology. 2020. DOI: https://doi.org/10.1212/WNL.0000000000011397.

Source: AAN, Neurology

https://honiton-hearing.co.uk/wp-content/uploads/2021/01/Honiton-ear-wax-removal.jpg 417 500 admin https://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.png admin2021-01-25 12:54:122021-01-25 12:54:58Primary Progressive Aphasia Memory Loss Measured

Oticon hearing aids

January 20, 2021/in Exeter hearing aids, News /by admin

Oticon Launches Oticon More at 2021 OticonNext Event

 

Oticon Launches Oticon More at 2021 OticonNext Event

Oticon announced that over 5,000 hearing care professionals registered to join the company for its 2021 OticonNext “Discover More” Conference, the company’s “biggest ever launch event for a new product.” The live, virtual knowledge-sharing experience introduced participants to Oticon More, “the world’s first hearing aid with an on-board deep neural network.”  This new hearing aid is said to build on Oticon’s “proven BrainHearing approach to deliver a full and precisely balanced sound scene that makes it easier for the brain to perform optimally.” Oticon President Gary Rosenblum and Oticon staff experts showed conference participants how Oticon More represents a “fundamentally new approach” to signal processing.

Related article: Oticon Launches Oticon More Hearing Aid

“Through the OticonNext Conference, we aimed to equip practitioners with the knowledge and tools they need to continue to bring life-changing technology to patients,” said Rosenblum. “Over the past decade, Oticon has pioneered new standards and advanced its portfolio of hearing solutions dramatically. From our newest addition, Oticon More, to our innovative power and pediatric solutions, we continue to offer hearing care professionals and their patients one of the industry’s most comprehensive portfolios of hearing technology.”

Rosenblum shared recent honors for the new hearing solution with conference participants.  On January 11, the Consumer Electronics Association named Oticon More an honoree in the CES 2021 Innovation Awards in the Health & Wellness and Wearable Technologies categories. This is the fifth consecutive year that Oticon, Inc has been recognized by the international awards program that annually selects the best of the best in consumer electronics. The most recent awards bring to an even dozen the number of times Oticon has been honored by the CES Innovation Awards program.

Inspiration, Innovation, and Practice Support 

Keynote speaker Dan Buettner, author of The Blue Zones: Lessons for Living Longer from the People Who’ve Lived the Longest, provided guidance on how technology like Oticon More contributes to health and long life by enabling patients to maintain vital connections to people and the world. A panel discussion addressed questions from the online audience on Oticon More’s technology innovations, including the new Polaris platform. Following the conference, hearing care professionals were invited to explore The Zone exhibit hall to learn more about the variety of clinical and business support available through Oticon and the company’s business partners.

Interactive Webisodes Continue Knowledge Sharing

The conference’s interactive virtual format extends beyond the launch event with a series of post-conference educational webisodes that build on the knowledge gained at OticonNext. The live interactive sessions take a deeper dive into the audiology of Oticon More and the new research that shows the brain needs access to all sounds—not just speech—in order to work in a natural way. Scheduled for February and March, the five webisodes each last approximately one hour and require prior registration.

Learn more about Oticon More and the entire portfolio of Oticon hearing solutions with BrainHearing technology at: www.Oticon.com/More.

Available at the Honiton hearing centre near Exeter Devon

Source: Oticon

Images: Oticon

https://honiton-hearing.co.uk/wp-content/uploads/2019/02/Honiton-Devon-ear-wax-removal-Exeter-Tiverton-Lyme-Bay.png 640 640 admin https://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.png admin2021-01-20 10:44:382021-01-20 10:44:38Oticon hearing aids

New Drug Promises Relief from Tinnitus

January 9, 2021/in News, Tinnitus /by admin

New Drug Promises Relief from Tinnitus, Epilepsy

  

New Drug Promises Relief from Tinnitus, Epilepsy

Neurophysiologists at the University of Connecticut (UConn) have discovered a new drug that may prevent tinnitus and treat epilepsy by selectively affecting potassium channels in the brain. According to an article in the June 10, 2015 edition of The Journal of Neuroscience, Anastasios V. Tzingounis, PhD, and colleagues say that both tinnitus and epilepsy are caused by overly excitable cells that flood the brain with an overload of signals that can lead to seizures (epilepsy) or phantom ringing in the ears (tinnitus).

The authors report that roughly 65 million people worldwide are affected by epilepsy. While exact statistics on tinnitus are not easy to determine, the American Tinnutus Association estimates that two million people in the US suffer from disabling tinnitus.

Anastasios V. Tzingounis, PhD

Anastasios V. Tzingounis, PhD, University of Connecticut

According to Tzingounis and co-authors, the existing drugs available to treat epilepsy don’t always work and can have serious side effects. One of the more effective drugs, retigabine, helps open KCNQ potassium channels, which serve as the “brakes” that shut down the signaling of overly excited nerves. Retigabine, however, has terrible side effects and is usually only given to adults who don’t get relief from other epilepsy drugs. The side effects of retigabine include sleepiness, dizziness, problems with hearing and urination, and a disturbing tendency to turn patients’ skin and eyes blue.

In 2013, Tzingounis began collaborating with Thanos Tzounopoulos, PhD, a tinnitus expert at the University of Pittsburgh, to create a new drug candidate. The new drug, SF0034, was chemically identical to retigabine, but included an extra fluorine atom. Originally developed by SciFluor, the company wanted to know whether the compound had promise for treating epilepsy and tinnitus.

Thanos Tzounopoulos, PhD,

Thanos Tzounopoulos, PhD, University of Pittsburgh

Tzingounis and Tzounopoulos thought the drug had the potential to be much better than retigabine in treating both conditions. They first had to determine if SF0034 worked on KCNQ potassium channels the same way retigabine does, and if so, if it would be better or worse.

The co-authors explain in their article that KCNQ potassium channels are found in the initial segment of axons, long nerve fibers that reach out and almost touch other cells. The gap between the axon and the other cell is called a synapse. When the cell wants to signal to the axon, it floods the synapse with sodium ions to create an electrical potential. When that electrical potential goes on too long, or gets overactive, the KCNQ potassium channel kicks in. The result is that it opens, potassium ions flood out, and the sodium-induced electrical potential shuts down.

In some types of epilepsy, the KCNQ potassium channels have trouble opening and shutting down runaway electrical potentials in the nerve synapse. Retigabine helps them open. According to the authors, there are five different kinds of KCNQ potassium channels in the body, but only two are important in epilepsy and tinnitus: KCNQ2 and KCNQ3. The problem with retigabine is that it acts on other KCNQ potassium channels as well. That’s why it has so many unwanted side effects.

When testing SF0034 in neurons, the researchers found that it was more selective than retigabine. It appeared to open only KCNQ2 and KCNQ3 potassium channels, and to not affect the KCNQ 4 or 5 potassium channels. The research showed that SF0034 was more effective than retigabine at preventing seizures in animals, and it was also less toxic.

The results are promising, and SciFluor plans to start FDA trials with SF0034 to test its safety and efficacy in people. Treating epilepsy is the primary goal, but treating or preventing tinnitus is a secondary goal.

Source: UConn; Medical News Today

Photo credits: University of Connecticut; University of Pittsburgh; © Skypixel | Dreamstime.com

https://honiton-hearing.co.uk/wp-content/uploads/2019/03/Honiton-hearing-aids-Devon-2019.jpg 360 640 admin https://honitonnew.leecurran.co.uk/wp-content/uploads/2018/03/honitonhearinglogo.png admin2021-01-09 15:16:472021-01-09 15:16:47New Drug Promises Relief from Tinnitus

Archive

  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018

Categories

  • Benefits of hearing aids
  • Depression
  • Depression and Hearing
  • Devon Ear syringing centre
  • Ear wax removal Devon
  • Ear wax removal Exeter
  • Earwax removal
  • Exeter hearing aids
  • Hearing aid batteries
  • Hearing aids
  • Hearing aids Devon
  • Hearing aids Exeter
  • Hearing loss
  • Hearing tests Devon
  • Honiton hearing aids
  • Hopi candles in Devon
  • News
  • Personal
  • Sound Watch
  • Streaming
  • Tinnitus
  • Uncategorized
  • Videos
  • Widex Moment hearing aids

Facebook

Instagram

Instagram did not return a 200. Follow Me!

Areas that Honiton Hearing Centre services:

Exeter, Exmouth, Lyme Regis Bridport,Taunton, Wellington Tiverton, Honiton, Sidmouth, Ottery St Mary, Sidford, Axminster, Charmouth, Horton, Ilminster,Dunkeswell, East Budleigh, Sudbury, Branscombe, Beer, Seaton,Whimple, Clyst Honiton, Topsham, West Hill, Fairmile, Culmstock, Wiveliscombe, Dulverton, Bampton, Oakfordbridge, Morebath,Rackenford, Cove, Catworthy, Norton Fitzwarren, White Ball, Huntsham, Milverton, Bishops Lydeard, Chard, Beaminster, Crewkerne, South Petherton, Tytherleigh

Honiton Hearing Centre

12 New St, Honiton Devon
EX14 1EY

01404 47070 or 01884 255722

Please note: WE DO NOT SUPPLY GOODS OUTSIDE THE UK

Opening Hours

9:15-16:30 Mon-Fri
Closed on Saturday
Closed on Sunday

© Copyright - honitonhearing.co.uk - powered by leecurran.co.uk
  • Youtube
  • Twitter
  • Facebook
  • Linkedin
  • Gplus

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Honiton Hearing Centre
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Scroll to top